In the latest episode of Touching Base, we discuss big news in CRISPR along with updates in the business side of biotech.

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...

CRISPR Therapeutics recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and diluted loss ...

Cell and gene therapy start-up NKure Therapeutics and international gene-editing company CRISPR Therapeutics have entered into a partnership to co-develop and co-commercialise CTX112 — a next ...

Now, a first-in-human clinical trial is testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal cancers. The results show encouraging signs of safety ...

CRISPR Therapeutics stock is heavily shorted in the weeks going into earnings The short-sellers are betting against the name in a big way, with more than 20 million shares sold short as of the ...

Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy contract development and manufacturing organization (CDMO), has manufactured viral vector with its AAV Curator Platform ...

Prasad's social media reveals criticism of Verve's 1st-gen PCSK9 approach, which may signal negative sentiment for CRISPR to navigate. Unlock your all-in-one trading dashboard with real-time ...

A few years ago, a British company called Genus set out to design pigs immune to this germ using CRISPR gene editing. Not only did they succeed, but its pigs are now poised to enter the food chain ...

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimates of a loss of $1.21 per share.

ZUG, Switzerland and BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...